Bone-anchored hearing implant simulator — titanium fixture osseointegration, direct bone conduction, and skull-bypass sound transmission
Bone-anchored hearing systems bypass the outer and middle ear by driving sound directly through the skull to the cochlea. They are indicated when conventional air-conduction hearing aids cannot be worn or cannot help: conductive or mixed hearing loss with a persistent air-bone gap, chronic drainage that precludes an occluding earmold, congenital aural atresia, or single-sided deafness (SSD) where one cochlea no longer functions at all.
Conductive and mixed hearing loss: An air-bone gap develops when sound cannot efficiently reach the cochlea via the ear canal and ossicular chain — otosclerosis, ossicular discontinuity, or tympanic membrane perforation. If cochlear (bone-conduction) thresholds remain reasonable (≤45 dB HL), routing sound around the damaged conductive pathway restores near-normal hearing.
Chronic ear disease: Chronic suppurative otitis media, cholesteatoma, and radical mastoid cavities frequently preclude a conventional in-canal or behind-the-ear hearing aid: an occluding earmold traps moisture, worsens drainage, and causes recurrent infection. A bone conductor sits on intact skin away from the diseased canal entirely.
Congenital aural atresia / microtia: Children born without a functioning ear canal (often with a normal cochlea) cannot be fitted with conventional aids at all. A percutaneous or transcutaneous bone conductor, trialled first on a softband, is frequently the primary rehabilitation strategy from infancy through school age.
Single-sided deafness (SSD): When one cochlea is completely non-functional (post-acoustic-neuroma surgery, sudden sensorineural loss, Meniere's disease) but the contralateral ear is normal, a bone conductor implanted on the deaf side transmits sound transcranially through the skull to the good cochlea — restoring a sense of sound on the deaf side and improving the head shadow effect in noise.
Before committing to surgery, every candidate trials a test-band or softband processor pressed against the mastoid for 2–4 weeks. If aided bone-conduction thresholds and speech scores on the softband predict meaningful benefit, only then is implantation offered — a cheap, reversible screen that avoids surgery in the small fraction of patients who will not benefit.
Air-conduction hearing aids amplify sound delivered through an earmold into a functioning ear canal and vibrate an intact tympanic membrane/ossicular chain. This pathway is unavailable or actively harmful in the target population: an atretic canal has no eardrum to vibrate; a draining chronic-otitis ear becomes infected under an occluding mold; a dead cochlea on the SSD side cannot be amplified into function no matter how loud the aid is driven.
CROS (contralateral routing of signal) aids — a wireless microphone on the deaf ear transmitting to a receiver on the good ear — are the non-surgical alternative for SSD, but many patients find the occlusion of the good ear and the electronic routing less natural than direct bone conduction, and speech-in-noise performance is generally inferior to a well-fitted bone-anchored implant.
Surgery places a titanium (or titanium-zirconium) fixture into the dense cortical bone of the mastoid, roughly 5.5–6.5 cm behind the ear canal to keep the sound processor clear of the pinna. Three coupling philosophies exist today, trading transmission efficiency against skin complication risk and imaging compatibility.
Cochlear Baha Connect (Baha 6 Max sound processor) and Oticon Medical Ponto 4 use a titanium abutment that penetrates the skin, snap-coupling the external processor directly onto the bone-anchored fixture. Because vibration travels through a rigid metal-to-metal interface with no intervening soft tissue, percutaneous coupling delivers the highest transmission efficiency and the widest usable bandwidth of any bone-conduction system — but the permanent skin-penetration site requires lifelong daily hygiene and carries the highest (though still modest) risk of local skin reactions.
Surgical technique has been simplified dramatically since 1977: modern minimally invasive punch/drill techniques (MIPS, Linear incision) create the abutment site through a small dermatome punch rather than a large skin flap, reducing soft-tissue thickness around the abutment (a major driver of skin complications) and cutting operative time to under 20 minutes in many centers.
Passive transcutaneous (Cochlear Baha Attract, Ponto with magnet): the implanted fixture connects to a subdermal magnet; an external processor holds a matching magnet against intact skin. No permanent skin opening exists, essentially eliminating chronic abutment skin reactions and improving cosmesis, at the cost of vibration energy dissipated crossing skin and subcutaneous fat — a real, measurable transmission penalty, especially at higher frequencies.
Active transcutaneous (Cochlear Osia 2, MED-EL Bonebridge): rather than transmitting vibration through skin, the actuator itself is implanted beneath intact skin and vibrates the bone directly. Osia 2 uses a piezoelectric "Piezo Power" transducer bonded to the fixture; Bonebridge uses an electromagnetic floating-mass transducer (BC-FMT) seated in a bony well. Because the vibrating element sits internally, active systems recover most of the efficiency lost by passive magnetic coupling while keeping skin fully intact.
Choice of system is rarely purely audiological: percutaneous abutments remain preferred for maximum gain in severe mixed losses and for patients needing frequent MRI (older transcutaneous magnets could require surgical removal before high-field MRI; newer magnet designs are now MRI-conditional up to 3T with magnet rotation).
Osseointegration is the direct structural and functional connection between living bone and the surface of a load-bearing titanium implant, with no intervening fibrous soft-tissue layer — the biological principle underlying every bone-anchored hearing system, dental implant, and osseointegrated limb prosthesis in use today.
In 1952, Swedish orthopedic researcher Per-Ingvar Brånemark implanted titanium optical chambers into rabbit fibulae to study bone marrow microcirculation. When he tried to retrieve the chambers, he found the titanium had fused so completely with living bone that it could not be removed without damaging the bone itself. Brånemark coined the term "osseointegration" and spent the next two decades demonstrating that titanium's stable surface oxide layer (TiO2) allows bone cells to deposit mineralized matrix in direct molecular contact with the metal — rather than walling it off with scar (fibrous) tissue, as happens with most other implanted materials.
The first titanium dental implant was placed in a human in 1965; the first bone-anchored hearing implant followed in 1977, placed by Anders Tjellström in Gothenburg, Sweden — proving that the same fixture technology could carry sound vibration as reliably as it carries chewing load.
Bone-implant contact (BIC) — the percentage of the implant surface in direct histological contact with mineralized bone rather than fibrous tissue — rises through a predictable biological sequence after placement:
Weeks 0–1 (primary stability): stability is purely mechanical — the threaded fixture is press-fit into the drilled osteotomy. BIC ≈ 0–5%. A blood clot forms around the implant surface.
Weeks 1–3 (woven bone formation / remodeling dip): osteoclasts resorb micro-damaged bone from drilling while osteoblasts lay down disorganized woven bone. Mechanical (implant stability quotient, ISQ) readings can dip slightly here as mineralized-but-immature bone temporarily replaces the tight mechanical press-fit of week 0 — a well-documented phenomenon in resonance-frequency analysis literature.
Weeks 3–8 (secondary stability rises): woven bone is progressively remodeled into organized lamellar bone directly apposed to the titanium oxide surface. BIC climbs from roughly 30% to 65–75% on modern moderately-rough (e.g., TiOblast, SLA-equivalent) surfaces.
Weeks 8–12+ (maturation): lamellar bone remodeling continues; BIC plateaus around 85–92% for well-integrated fixtures — never reaching 100%, since some marrow space and vasculature always persists between threads.
Modern wide-diameter (4.5mm), rough-surfaced fixtures achieve sufficient secondary stability to support processor loading at 3–4 weeks in adults with good bone quality — a dramatic reduction from the original 1977 Brånemark protocol, which mandated 3–6 months of unloaded healing before the first abutment-coupled sound processor was ever connected.
Implant Stability Quotient (ISQ), measured non-invasively with resonance frequency analysis (e.g., the Osstell system), quantifies how rigidly the fixture is held by surrounding bone on a 1–100 scale. A small magnetic peg (SmartPeg) is attached to the fixture and excited by a magnetic pulse; the resonance frequency returned is converted to ISQ.
ISQ 55–65 at placement reflects primary mechanical stability alone. Values commonly dip by 3–8 ISQ points during weeks 2–4 as woven bone remodeling temporarily reduces rigidity, then climb steadily as lamellar bone matures — typically reaching ISQ 65–80 by 12 weeks. ISQ trends, not single readings, guide the clinical decision of when a fixture is safe to load with a sound processor, particularly in pediatric, irradiated, or thin-bone patients where healing is slower and less predictable.
Once secondary stability is confirmed, the external sound processor is coupled to the abutment or magnet and activated. From this moment, incoming sound is captured electronically, shaped by the fitting software, and delivered as mechanical vibration straight into the skull — a pathway that entirely bypasses a damaged or absent outer and middle ear.
The external processor houses one or more directional microphones, a digital signal processor (DSP) chip running noise reduction and multi-channel compression, and an electromechanical transducer. In percutaneous systems the transducer sits inside the processor housing itself and drives the abutment snap-coupling directly. In active transcutaneous systems (Osia 2, Bonebridge) the transducer is implanted, and the external unit only transmits a radiofrequency-encoded audio signal and power across intact skin to the internal actuator — the actual vibration is generated beneath the skin, not transmitted through it.
Once vibration reaches the titanium fixture, it propagates as a mechanical wave through the temporal bone. Unlike air-conducted sound, which must cross the ear canal, set the eardrum and three ossicles into motion, and finally displace cochlear fluid through the oval window, bone-conducted vibration excites the cochlear fluids directly through the temporal bone — the outer and middle ear pathway is functionally irrelevant to the signal reaching the inner ear.
Activation typically occurs 3–12 weeks post-surgery depending on fixture design, bone quality, and pediatric vs. adult status. The audiologist uses manufacturer fitting software (Cochlear's Baha Fitting Software, Oticon Medical Genie, MED-EL Maestro) referenced to the patient's bone-conduction audiogram to set frequency-specific gain targets, generally following a prescriptive formula analogous to NAL-NL2 or DSL adapted for bone conduction.
Direct bone conduction thresholds are measured in-situ (aided) using the actual implanted transducer coupled to the skull — a more accurate real-world measurement than the pre-surgical softband trial, since skin/soft-tissue damping (for transcutaneous systems) and individual skull bone density both influence the transfer function from processor to cochlea.
Outcome measurement compares unaided vs. aided hearing thresholds (functional gain), speech recognition in quiet and in noise, and — critically for choosing between percutaneous and transcutaneous systems — how much vibration energy is lost crossing intact skin versus a direct metal-to-bone interface.
Because percutaneous abutments couple the processor's transducer directly to titanium bonded into bone, essentially all generated vibration energy is delivered to the skeleton. Passive transcutaneous systems must instead drive vibration across a magnet, skin, and subcutaneous soft tissue — a lossy mechanical interface. Published comparative studies consistently report 5–15 dB less output at the cochlea for passive transcutaneous devices at equivalent input, with the gap widening at higher frequencies (>3 kHz) where soft tissue damping is most pronounced.
Active transcutaneous systems (Osia 2, Bonebridge) close much of this gap by implanting the vibrating actuator itself beneath the skin rather than transmitting vibration through it: head-to-head studies report Osia 2 users achieving aided thresholds and speech scores comparable to percutaneous Baha 6 users, and significantly better than passive magnetic (Baha Attract) users, particularly for higher-frequency speech information carrying consonant detail.
For SSD patients, the implant does not restore true binaural hearing (the deafened cochlea remains non-functional) — instead it exploits transcranial bone conduction so that sound arriving at the deaf ear reaches the good cochlea, eliminating the "head shadow" effect that otherwise degrades speech understanding when noise or the talker is on the deaf side. Controlled studies report SNR improvements on the order of 3–4 dB in these configurations, translating into clinically meaningful gains in speech-in-noise questionnaires (e.g., SSQ, APHAB) and reduced listening effort.
For conductive/mixed losses, functional gain of 25–35 dB restores audibility across the speech frequency range, with word recognition scores in quiet frequently reaching 80–100% aided, versus severely reduced unaided performance limited by the conductive component.
Skin reactions around percutaneous abutments are graded using the Holgers classification: Grade 0 (no redness), Grade 1 (mild redness, no treatment), Grade 2 (redness + moist tissue, topical treatment), Grade 3 (granulation tissue, requires intervention), Grade 4 (infection requiring abutment/fixture removal). Most published series report the large majority of reactions fall into Grades 0–1 in any given year, with severe Grade 3–4 reactions substantially less common; modern minimally invasive surgical techniques and hydroxyapatite-coated abutments have further reduced reaction rates compared with early linear-incision techniques.
Implant (fixture) loss/extrusion — failure of osseointegration itself rather than a skin reaction — occurs in roughly 2–8% of cases over 3–5 years with legacy narrow (3.75mm) fixtures, concentrated in irradiated bone, pediatric patients, and smokers. Modern wide-diameter (4.5mm), rough-surfaced fixtures have pushed reported 3-year survival above 95–98% in several large registries.
A widely cited long-term Swedish registry following the original Gothenburg BAHA cohort (implants placed from 1977 onward) reported implant survival exceeding 90% at 10+ years for the earliest percutaneous fixtures — remarkable durability for a device design predating the modern dental-implant literature it ultimately helped inspire.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Cochlear Baha 6 Max / Connect | Snap-coupled external transducer, direct titanium-to-bone drive | Highest transmission efficiency, widest bandwidth | |
| Cochlear Baha Attract | External transducer vibrates through skin + subdermal magnet pair | No permanent skin opening, easier hygiene | |
| Cochlear Osia 2 | Implanted Piezo Power actuator vibrates bone directly beneath intact skin | Near-percutaneous efficiency, skin fully closed | |
| MED-EL Bonebridge | Electromagnetic floating-mass transducer (BC-FMT) in bony well | Deep-seated actuator, good for thin overlying soft tissue | |
| Oticon Medical Ponto 4 | Wide-diameter (4.5mm) fixture, accelerated loading protocols | Shortened healing-to-activation window |
Bone-anchored hearing implants are lifelong devices requiring annual audiological and skin review. Beyond the individual implant, two special populations shape long-term practice: children with bilateral conditions who need binaural input for language development, and adults with bilateral conductive loss who benefit from restored sound localization.
Children with congenital bilateral aural atresia or bilateral conductive loss cannot wait years for surgical candidacy without risking permanent delays in speech and language development. The standard pathway starts a softband bone-conduction processor in infancy — as soon as hearing loss is confirmed — providing bone-conducted sound access with zero surgical risk while the skull grows.
Surgical implantation is generally deferred until approximately age 5, when calvarial bone thickness (typically ≥2.5–3mm at the mastoid) is sufficient to reliably host a fixture without breaching the dura or sigmoid sinus. Some centers now use shorter, narrower pediatric-specific fixtures and staged two-step surgical protocols (fixture placement, then delayed abutment connection several months later) to reduce the risk of accidental trauma to an unhealed implant in an active child.
Unlike SSD (where only one implant is used, since only one cochlea functions), patients with bilateral conductive or mixed hearing loss — bilateral chronic ear disease or bilateral atresia — can receive bone-anchored implants on both sides. Bilateral fitting restores access to interaural time and level difference cues that a single bone conductor cannot provide, meaningfully improving sound source localization and speech-in-noise performance in complex listening environments compared to a unilateral fitting, at the cost of a second surgical site and device.
Long-term surveillance combines three parallel checks at each annual (or more frequent, in the first year) visit:
Skin and soft tissue: Holgers grading around percutaneous abutments; inspection of magnet-pocket skin for pressure necrosis in transcutaneous systems, which can occur if too strong a magnet is selected for the overlying soft-tissue thickness.
Implant stability and osseointegration: periodic ISQ measurement (resonance frequency analysis) to confirm the fixture remains stable; a declining ISQ trend over successive visits can be an early warning sign of fixture loosening before clinical mobility is detectable.
Audiological performance: annual aided thresholds and speech-in-noise scores to catch progressive underlying sensorineural loss, processor malfunction, or a growing transcutaneous efficiency gap as children's soft tissue thickens with growth — all managed by processor reprogramming, magnet strength adjustment, or occasionally revision surgery.
Because osseointegration is a permanent biological bond rather than a mechanical friction fit, a properly integrated fixture that survives the first postoperative year has an excellent long-term prognosis — most fixture losses that do occur happen early, during the vulnerable healing window before mature lamellar bone has fully formed.